Abstract
The influence of age of onset of Parkinson's disease on the severity and the pattern of motor symptoms was investigated by comparing the motor scores with and without levodopa therapy in two groups of patients divided according to age of onset (early less than 50, late greater than 60 years) and matched for disease duration (n = 69 in each group, Study I). The baseline score, that is, the motor disability of patients when off levodopa, was similar in the early- and late- onset groups. In contrast, the residual motor score, assessed when the effect of levodopa treatment was maximum and stable, was significantly higher in the late onset group. When the two groups of patients were matched, in addition, for their residual motor score, (n = 54 in each group, Study II), no difference was observed between the early and late onset groups, except for gait disorder which was more severe in older patients. These results suggest that age of onset mainly affects the response to levodopa therapy, because it may increase the prevalence of non-dopaminergic lesions of the brain, including those responsible for gait disorders.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bonnet A. M., Loria Y., Saint-Hilaire M. H., Lhermitte F., Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology. 1987 Sep;37(9):1539–1542. doi: 10.1212/wnl.37.9.1539. [DOI] [PubMed] [Google Scholar]
- Cedarbaum J. M., McDowell F. H. Sixteen-year follow-up of 100 patients begun on levodopa in 1968: emerging problems. Adv Neurol. 1987;45:469–472. [PubMed] [Google Scholar]
- Diamond S. G., Markham C. H., Hoehn M. M., McDowell F. H., Muenter M. D. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology. 1989 Sep;39(9):1187–1190. doi: 10.1212/wnl.39.9.1187. [DOI] [PubMed] [Google Scholar]
- Dubois B., Pillon B., Sternic N., Lhermitte F., Agid Y. Age-induced cognitive disturbances in Parkinson's disease. Neurology. 1990 Jan;40(1):38–41. doi: 10.1212/wnl.40.1.38. [DOI] [PubMed] [Google Scholar]
- Esteguy M., Bonnet A. M., Kefalos J., Lhermitte F., Agid Y. Le test à la L-Dopa dans la maladie de Parkinson. Rev Neurol (Paris) 1985;141(5):413–415. [PubMed] [Google Scholar]
- Hietanen M., Teräväinen H. The effect of age of disease onset on neuropsychological performance in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 Feb;51(2):244–249. doi: 10.1136/jnnp.51.2.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lhermitte F., Agid Y., Signoret J. L. Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol. 1978 May;35(5):261–263. doi: 10.1001/archneur.1978.00500290007002. [DOI] [PubMed] [Google Scholar]
- Lieberman A., Dziatolowski M., Kupersmith M., Serby M., Goodgold A., Korein J., Goldstein M. Dementia in Parkinson Disease. Ann Neurol. 1979 Oct;6(4):355–359. doi: 10.1002/ana.410060409. [DOI] [PubMed] [Google Scholar]